Evidence map›Paper›PMID 42642426›Full record

ArticleNature communications2026

DICER1-related tumour predisposition mutations increase 3p-miRNA function and HERVH activity.

Katrina Gordon, Nicolas Bellora, Jeroen Witteveldt, Joanna K Wojtus, Felix Mueller, Katharina J Kases, Pilar G Marchante, Guillermo Peris, Shelagh Boyle, Sara R Heras and 3 more

Abstract read
In one paragraph

Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Katrina GordonInstitute of Immunology and Infection Research, Ashworth Laboratories, School of Biological Sciences, University of Edinburgh, Edinburgh, UK.
Nicolas BelloraNational Scientific and Technical Research Council (CONICET), San Carlos de Bariloche, Argentina.ORCID http://orcid.org/0000-0001-6637-3465
Jeroen WitteveldtInstitute of Immunology and Infection Research, Ashworth Laboratories, School of Biological Sciences, University of Edinburgh, Edinburgh, UK.ORCID http://orcid.org/0000-0001-8247-7010
Joanna K WojtusInstitute of Immunology and Infection Research, Ashworth Laboratories, School of Biological Sciences, University of Edinburgh, Edinburgh, UK.
Felix MuellerInstitute of Immunology and Infection Research, Ashworth Laboratories, School of Biological Sciences, University of Edinburgh, Edinburgh, UK.
Katharina J KasesInstitute of Immunology and Infection Research, Ashworth Laboratories, School of Biological Sciences, University of Edinburgh, Edinburgh, UK.
Pilar G MarchanteGENYO, Centre for Genomics and Oncological Research: Pfizer/University of Granada/Andalusian Regional Government, PTS Granada, Granada, Spain.ORCID http://orcid.org/0009-0000-8206-6860
Guillermo PerisGENYO, Centre for Genomics and Oncological Research: Pfizer/University of Granada/Andalusian Regional Government, PTS Granada, Granada, Spain.ORCID http://orcid.org/0000-0003-2010-7844
Shelagh BoyleMRC Human Genetics Unit, Institute of Genetics and Cancer, University of Edinburgh, Edinburgh, UK.
Sara R HerasGENYO, Centre for Genomics and Oncological Research: Pfizer/University of Granada/Andalusian Regional Government, PTS Granada, Granada, Spain.ORCID http://orcid.org/0000-0003-1677-7685
Atlanta G CookInstitute of Quantitative Biology, Biochemistry and Biotechnology, Max Born Crescent, University of Edinburgh, Edinburgh, UK.ORCID http://orcid.org/0000-0003-2087-9772
Cei Abreu-GoodgerInstitute of Ecology and Evolution, School of Biological Sciences, The University of Edinburgh, Edinburgh, UK.ORCID http://orcid.org/0000-0001-8302-9893
Sara MaciasInstitute of Immunology and Infection Research, Ashworth Laboratories, School of Biological Sciences, University of Edinburgh, Edinburgh, UK. smacias@ed.ac.uk.ORCID http://orcid.org/0000-0002-0643-3494

Funding

Leverhulme Trust RPG-2020-355Wellcome TrustWellcome Trust (Wellcome) 107665/Z/15/ZWellcome Trust (Wellcome) 221737/Z/20/Z
6 · The paper itself

Abstract

The DICER1 gene is mutated in cancer, including in DICER1-related tumour predisposition. Cancer-associated hotspot mutations have been reported in both catalytic domains of DICER and are predicted to disrupt miRNA biogenesis. To understand how these hotspot mutations contribute to cancer development, we generate cell lines harbouring single amino acid substitutions within the catalytic RNase IIIa (S1344L) or RNase IIIb (D1709N) domains of the endogenous DICER1 gene. Here we show that both mutations result in a widespread loss of 5p miRNAs, and an increase in 3p passenger strands loading into AGO2. The shared similarities between both mutants can be attributed to the structural proximity of the S1344 residue to the RNase IIIb catalytic centre. Functionally, we find that changes in the repertoire of miRNAs loaded into AGO2 result in altered gene expression, impacting critical pathways for cancer development. Additionally, our results indicate that inactivating the processing activity of DICER does not result in genomic instability. Instead, mutations cause upregulation of transposable elements, including the human endogenous retrovirus H through miRNA-independent mechanisms. This suggests that both canonical and non-canonical DICER functions are important to understand DICER1-related tumour predisposition.

Indexed as

DEAD-box RNA HelicasesGenetic Predisposition to DiseaseMicroRNAsMutationNeoplasmsRibonuclease IIIArgonaute ProteinsCatalytic DomainCell Line, TumorGene Expression Regulation, NeoplasticHumansAGO2 protein, humanArgonaute ProteinsDEAD-box RNA HelicasesDICER1 protein, humanMicroRNAsRibonuclease III

Identifiers

PMID42642426
PMCPMC13507251

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.